RxDoctor Payments DataLook up a doctor →

Baha Abu-Esheh, MD

Neurology · Ardmore, OKNPI 1619909934

Payments from drug & device makers

$272,992in general payments, 2019–2025

Across 1,115 payments — averaging $244.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$113K
  • AbbVie$50K
  • Lilly USA, LLC$48K
  • H. Lundbeck A S$24K
  • Harmony Biosciences LLC$20K
  • Eli Lilly$7K
  • plus $11K from 53 others
$5,063in research payments, 2019–2025

Across 1 payment — averaging $5062.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$5K

What the payments were for

  • Consulting fees$23,56310%
  • Speaking & faculty fees$164,00671%
  • Travel & lodging$24,88311%
  • Food & beverage$17,2718%
  • Education$1550%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen149$113,401
AbbVie(2 entities)161$49,935
Lilly USA, LLC106$47,628
H. Lundbeck A S15$23,669
Harmony Biosciences LLC19$19,653
Eli Lilly1$7,350
UCB, Inc.110$1,666
Livanova USA, Inc.45$1,529
Teva Pharmaceuticals USA, Inc.71$1,027
Neurocrine Biosciences, Inc.42$718
SK Life Science, Inc.40$657
Acadia Pharmaceuticals Inc38$654
EMD Serono, Inc.37$569
Eisai Inc.23$423
Sunovion Pharmaceuticals Inc.28$358
Novartis19$328
Lundbeck LLC16$298
Biohaven Pharmaceutical Holding Company Ltd.26$241
Amneal Pharmaceuticals LLC14$239
Supernus Pharmaceuticals, Inc.13$217
Jazz Pharmaceuticals Inc.5$187
Neurelis, Inc.10$183
MDD US Operations, LLC8$175
Upsher-smith Laboratories LLC11$173
Corium, LLC9$157
AstraZeneca(2 entities)7$147
Biohaven Pharmaceuticals, Inc.14$138
GE HealthCare6$117
Inspire Medical Systems, Inc.5$99
Merz Pharmaceuticals, LLC4$85
Sumitomo Pharma America, Inc.11$71
Avion Pharmaceuticals4$70
Biogen4$67
Pfizer4$67
Avanir Pharmaceuticals, Inc.4$62
Argenx US, Inc.3$58
TG Therapeutics, Inc.3$55
Genentech USA, Inc.3$55
Catalyst Pharmaceuticals, Inc.2$43
E.r. Squibb & Sons, L.L.C.2$38
Impel Pharmaceuticals Inc.2$35
Scilex Pharmaceuticals Inc.2$33
Tanabe Pharma America, Inc.2$32
Kyowa Kirin, Inc.2$32
Microtransponder, Inc.1$23
Axsome Therapeutics, Inc.1$23
Averitas Pharma Inc.1$21
Aquestive Therapeutics, Inc.1$21
Greenwich Biosciences, Inc.1$19
Alnylam Pharmaceuticals Inc.1$18
Neuronetics, Inc.1$17
Sanofi1$17
Medtronic1$16
Otsuka America Pharmaceutical, Inc.1$14
Idorsia Pharmaceuticals US Inc1$14
Cala Health, Inc.1$13
Arbor Pharmaceuticals, Inc.1$13
Promius Pharma LLC1$12
Almatica Pharma LLC1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$272,992 in reported general payments places this provider in the 90th percentile of 152 neurology providers in Oklahoma.

See all neurology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$948,959
Medicare patients
1,456
Services billed
6,945

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam222$315,717
XcopriCenobamate28$43,197
FycompaPerampanel24$30,966
NayzilamMidazolam25$29,477
AptiomEslicarbazepine Acetate14$29,131
BotoxOnabotulinumtoxina23$27,104
Lacosamide183$26,716
Nurtec OdtRimegepant Sulfate15$26,603
UbrelvyUbrogepant14$24,165
NuvigilArmodafinil11$12,098
Pregabalin250$7,737
Eszopiclone135$3,942
Clobazam13$2,243
Lamotrigine43$1,601
Memantine Hcl43$1,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Nayzilam$1,666$345,194247 claims
AbbVieBotox, Ubrelvy$49,935$51,26937 claims
SK Life Science, Inc.Xcopri$657$43,19728 claims
Eisai Inc.Fycompa$423$30,96624 claims
Sunovion Pharmaceuticals Inc.Aptiom$358$29,13114 claims
PfizerNurtec Odt$67$26,60315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 152 neurology providers in Oklahoma.

Other neurology in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →